Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$251.65
-0.7%
$233.35
$160.36
▼
$261.00
$37.20B0.11.21 million shs838,745 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
0.00%+2.03%+8.92%+21.16%+51.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$251.65
-0.7%
$233.35
$160.36
▼
$261.00
$37.20B0.11.21 million shs838,745 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
0.00%+2.03%+8.92%+21.16%+51.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$254.411.10% Upside

Current Analyst Ratings Breakdown

Latest BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingOverweight$245.00 ➝ $305.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$280.00 ➝ $300.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$251.00 ➝ $270.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
DowngradeHold (C) ➝ Hold (C-)
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetOutperform$256.00 ➝ $272.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetNeutral$212.00 ➝ $225.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$270.00 ➝ $300.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$248.00 ➝ $272.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetEqual Weight$231.00 ➝ $238.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$250.00 ➝ $260.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$10.30B3.61$22.49 per share11.19$124.45 per share2.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.34107.5415.792.873.37%9.38%5.69%N/A

Latest BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable

Recent News About These Companies

Biogened Pays Dividend for 2025 Financial Year
Biogen Inc. $BIIB Stake Lifted by Danske Bank A S
Biogen Inc. $BIIB Stock Acquired by Fifth Third Bancorp
Biogen Inc. $BIIB Stock: Allworth Financial LP Increases Stake

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biogen stock logo

Biogen NASDAQ:BIIB

$251.65 -1.75 (-0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$251.85 +0.20 (+0.08%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.